Key result
c-Mpl ligand fails to stimulate proplatelet formation in vitro but increases megakaryocyte viability.
Why the study?
Does recombinant human c-Mpl ligand stimulate proplatelet formation in isolated human megakaryocytes?
Does recombinant human c-Mpl ligand stimulate proplatelet formation in isolated human megakaryocytes?
Recombinant human c-Mpl ligand does not directly stimulate proplatelet formation in mature human megakaryocytes in vitro, though it improves cell viability.
c-Mpl ligand does not stimulate proplatelet formation in vitro; leaves open its role in megakaryocyte viability and in vivo platelet production.
To evaluate the effect of the c-Mpl ligand on platelet production by megakaryocytes, we investigated proplatelet formation in isolated human megakaryocytes cultured in serum-free medium, with or without the c-Mpl ligand, interleukin-6 and erythropoietin. When interleukin-6 was added to the culture medium, the percentage of megakaryocytes displaying proplatelets was approximately 1.5-fold the control value; whereas, in the presence of the c-Mpl ligand, the percentage of megakaryocytes displaying proplatelets decreased in a dose-dependent manner and did not increase compared to control values at any dose tested. However, the viability of megakaryocytes after a 4 d culture in the presence of the c-Mpl ligand was significantly higher than that of the cells cultured without it. The c-Mpl ligand did not stimulate the proplatelet formation in megakaryocytes in vitro.
No takes yet. Share an insight, caveat, or question.
Ito et al. (1996) studied this question. c-Mpl ligand vs. Without c-Mpl ligand (control) was evaluated on Proplatelet formation (percentage of megakaryocytes displaying proplatelets). The c-Mpl ligand did not stimulate proplatelet formation in isolated human megakaryocytes in vitro, though it significantly increased cell viability after a 4-day culture.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: